HC Wainwright Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $5.50

Plus Therapeutics (NASDAQ:PSTV) had its target price cut by analysts at HC Wainwright from $8.00 to $5.50 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 261.84% from the company’s previous close.

Several other research firms have also issued reports on PSTV. D. Boral Capital initiated coverage on shares of Plus Therapeutics in a research report on Monday, March 17th. They issued a “buy” rating and a $9.00 price target on the stock. Ascendiant Capital Markets reduced their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.

Plus Therapeutics Stock Up 3.4 %

Shares of PSTV stock opened at $1.52 on Friday. Plus Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.67. The company has a market cap of $8.96 million, a PE ratio of -0.60 and a beta of 0.73. The business’s 50 day moving average is $1.11 and its two-hundred day moving average is $1.24.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.